Hypophosphatemia Is Common After Intravenous Ferric Carboxymaltose Infusion Among Patients With Symptomatic Heart Failure With Reduced Ejection Fraction

2020 ◽  
Author(s):  
Alexander Dashwood ◽  
Cassandra Vale ◽  
Shaaheen Laher ◽  
Fiona Chui ◽  
Karen Hay ◽  
...  
Keyword(s):  
Heart Failure ◽  
Ejection Fraction ◽  
Ferric Carboxymaltose ◽  
Symptomatic Heart Failure ◽  
Reduced Ejection Fraction

scholarly journals Mildly symptomatic heart failure with reduced ejection fraction: diagnostic and therapeutic considerations

2020 ◽  
Vol 7 (4) ◽  
pp. 1477-1487
Author(s):  
Alexandra Arvanitaki ◽  
Eleni Michou ◽  
Andreas Kalogeropoulos ◽  
Haralambos Karvounis ◽  
George Giannakoulas
Keyword(s):  
Heart Failure ◽  
Ejection Fraction ◽  
Symptomatic Heart Failure ◽  
Reduced Ejection Fraction ◽  
Therapeutic Considerations

Pulmonary vascular response to exercise in symptomatic heart failure with reduced ejection fraction and pulmonary hypertension

2014 ◽  
Vol 17 (3) ◽  
pp. 320-328 ◽  
Author(s):  
Frederik H. Verbrugge ◽  
Matthias Dupont ◽  
Philippe B. Bertrand ◽  
Petra Nijst ◽  
Lars Grieten ◽  
...  
Keyword(s):  
Heart Failure ◽  
Pulmonary Hypertension ◽  
Ejection Fraction ◽  
Vascular Response ◽  
Symptomatic Heart Failure ◽  
Reduced Ejection Fraction ◽  
Response To Exercise

scholarly journals Medical Treatment of Heart Failure with Reduced Ejection Fraction – Improving Clinical Status and Functional Capacity

2017 ◽  
Vol 10 ◽  
Author(s):  
Cristiana Vitale ◽  
Giuseppe Rosano
Keyword(s):  
Heart Failure ◽  
Ejection Fraction ◽  
Functional Capacity ◽  
Clinical Status ◽  
Signs And Symptoms ◽  
Ferric Carboxymaltose ◽  
Reduced Ejection Fraction ◽  
Patients With Heart Failure ◽  
Effective Treatments

A contemporary review of treatments that have been shown to improve functional capacity in patients with Heart Failure and reduced Ejection Fraction (HFrEF).  The improvement of functional capacity is one of the main goals of treatment in patients with HFrEF. In the past, despite significant effects on exercise capacity some drugs (e.g. ibopamine, flosequinan) have shown detrimental effects on long- term outcomes in patients with HFrEF. It is perhaps notable that both of these drugs had shown signals of increased safety concerns during the earlier clinical phases of their development. The challenge is to encourage a timely identification of effective treatments that can enhance functional performance in HF without the more difficult and more expensive path to prove all drugs also reduce mortality. It is valuable to have approved and effective treatments that can do the first without the need for the second in all cases, provided adequate safety can be assured. Ivabradine, trimetazidine, ferric carboxymaltose and diuretics have consistently shown to improve functional capacity and symptoms in patients with HFrEF because of their effect on long term prognosis these drugs should always be considered in patients with heart failure. Diuretics improve functional capacity and should be prescribed in patients with signs and symptoms of congestions. Cardiac resynchronisation therapy improves functional capacity in patients with HFrEF in whom it is appropriately applied (QRS >130/150 msec according to morphology).

scholarly journals The therapeutic role of ivabradine in heart failure

2018 ◽  
Vol 9 (11) ◽  
pp. 199-207 ◽  
Author(s):  
Charles Badu-Boateng ◽  
Robert Jennings ◽  
Daniel Hammersley
Keyword(s):  
Heart Failure ◽  
Heart Rate ◽  
Clinical Trials ◽  
Ejection Fraction ◽  
Sinoatrial Node ◽  
Review Article ◽  
Clinical Use ◽  
Symptomatic Heart Failure ◽  
Reduced Ejection Fraction

Heart failure represents a major global cause of morbidity and mortality. Ivabradine is a selective funny current (If) inhibitor, which acts on the sinoatrial node, resulting in a reduction in heart rate. Ivabradine is currently licensed for use in patients with symptomatic heart failure with reduced ejection fraction and a heart rate persistently at least 70 beats per minute in spite of otherwise optimal prognostic heart failure pharmacotherapy. In this review article, we examine the mechanism of action of ivabradine, evaluate the clinical trials underpinning its application in heart failure and discuss its current recommended clinical use in this capacity.

scholarly journals 1 Sacubitril/valsartan in chronic symptomatic heart failure with reduced ejection fraction: first clinical experience from a large uk tertiary centre

Heart ◽  
2017 ◽  
Vol 103 (Suppl 5) ◽  
pp. A1.1-A1
Author(s):  
Danish Ali ◽  
Fiona Riley ◽  
Stephanie Kirkland ◽  
Jacqui Hyland ◽  
Prithwish Banerjee
Keyword(s):  
Heart Failure ◽  
Ejection Fraction ◽  
Clinical Experience ◽  
Symptomatic Heart Failure ◽  
Reduced Ejection Fraction ◽  
Tertiary Centre
Sign in / Sign up

Export Citation Format

Share Document